Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncolytic Virus Immunotherapy.
Marchini A, Ilkow CS, Melcher A. Marchini A, et al. Among authors: ilkow cs. Cancers (Basel). 2021 Jul 22;13(15):3672. doi: 10.3390/cancers13153672. Cancers (Basel). 2021. PMID: 34359574 Free PMC article.
Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies.
Fergusson DA, Wesch NL, Leung GJ, MacNeil JL, Conic I, Presseau J, Cobey KD, Diallo JS, Auer R, Kimmelman J, Kekre N, El-Sayes N, Krishnan R, Keller BA, Ilkow C, Lalu MM. Fergusson DA, et al. Mol Ther Oncolytics. 2019 May 21;14:179-187. doi: 10.1016/j.omto.2019.05.004. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31276026 Free PMC article.
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.
Wedge ME, Jennings VA, Crupi MJF, Poutou J, Jamieson T, Pelin A, Pugliese G, de Souza CT, Petryk J, Laight BJ, Boileau M, Taha Z, Alluqmani N, McKay HE, Pikor L, Khan ST, Azad T, Rezaei R, Austin B, He X, Mansfield D, Rose E, Brown EEF, Crawford N, Alkayyal A, Surendran A, Singaravelu R, Roy DG, Migneco G, McSweeney B, Cottee ML, Jacobus EJ, Keller BA, Yamaguchi TN, Boutros PC, Geoffrion M, Rayner KJ, Chatterjee A, Auer RC, Diallo JS, Gibbings D, tenOever BR, Melcher A, Bell JC, Ilkow CS. Wedge ME, et al. Among authors: ilkow cs. Nat Commun. 2022 Apr 7;13(1):1898. doi: 10.1038/s41467-022-29526-8. Nat Commun. 2022. PMID: 35393414 Free PMC article.
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, McComb S, Auer R, Diallo JS, Ilkow CS, Bell JC. Crupi MJF, et al. Among authors: ilkow cs. Front Immunol. 2022 Nov 3;13:1029269. doi: 10.3389/fimmu.2022.1029269. eCollection 2022. Front Immunol. 2022. PMID: 36405739 Free PMC article.
Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.
Martin NT, Crupi MJF, Taha Z, Poutou J, Whelan JT, Vallati S, Petryk J, Marius R, Austin B, Azad T, Boulanger M, Burgess T, Sanders I, Victoor C, Dickinson BC, Diallo JS, Ilkow CS, Bell JC. Martin NT, et al. Among authors: ilkow cs. Pharmaceuticals (Basel). 2023 May 7;16(5):709. doi: 10.3390/ph16050709. Pharmaceuticals (Basel). 2023. PMID: 37242495 Free PMC article.
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.
Taha Z, Crupi MJF, Alluqmani N, MacKenzie D, Vallati S, Whelan JT, Fareez F, Alwithenani A, Petryk J, Chen A, Spinelli MM, Ng K, Sobh J, de Souza CT, Bharadwa PR, Lee TKH, Thomas DA, Huang BZ, Kassas O, Poutou J, Gilchrist VH, Boulton S, Thomson M, Marius R, Hooshyar M, McComb S, Arulanandam R, Ilkow CS, Bell JC, Diallo JS. Taha Z, et al. Among authors: ilkow cs. Nat Commun. 2024 Aug 23;15(1):7267. doi: 10.1038/s41467-024-51498-0. Nat Commun. 2024. PMID: 39179564 Free PMC article.
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC. Parato KA, et al. Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20. Mol Ther. 2012. PMID: 22186794 Free PMC article.
57 results